NEWS
From June 16 to 18, 2026, the 24th CPHI China was successfully held at Shanghai New International Expo Centre.
Haohong (Qihe) Pharmaceutical Technology Co., Ltd. once again took part in this grand global pharmaceutical event. Our annual attendance reflects long-term commitment and serves as solid testimony to our stable operation and deep engagement in the global pharmaceutical market.
During the exhibition, our team held in-depth discussions and negotiations with new and existing customers at home and abroad, reaching multiple letters of intent for cooperation. Going forward, we will keep improving our products and services, and look forward to achieving win-win results together with more partners.
Haohong Pharmaceutical specializes in the R&D and custom manufacturing of innovative drug and generic drug intermediates. The company successfully obtained ISO9001:2015 Quality Management System Certification in 2024, was recognized as a Science and Technology-based Small & Medium-sized Enterprise in 2024, and awarded the title of Shandong Innovative Small & Medium-sized Enterprise in 2025.
Haohong Pharmaceutical boasts a high-caliber R&D team of more than 30 members, capable of developing over 50 new products annually, among whom 90% hold bachelor’s degrees or above.
We have a professional testing team equipped with more than ten imported analytical instruments, including HPLC, GC and other testing equipment.
Haohong Pharmaceutical features robust production capacity. Our manufacturing base in Liaocheng is equipped with 30 sets of reactors ranging from 3,000L to 5,000L, supporting an annual production capacity of 1, production capacity of 1,000 tons.
Haohong Pharmaceutical has dozens of advanced intermediates available for commercial production. Meanwhile, we provide efficient custom synthesis services ranging from gram scale to several hundred kilograms for customers.
Haohong Pharmaceutical’s core products are advanced intermediates, including:
Apalutamide、Enzalutamide、Darolutamide、Abemaciclib、Venetoclax、Cabozantinib、Macitentan、Alecitinib、Ponatinib、Pirtobrutinib、Ceritinib、Lazertinib、Zavegepant、Dabrafenib、vericiguat、
Olverembatinib、Mavacamten、Rosuvastatin a wide range of targeted drugs, anti-tumor active pharmaceutical ingredients and intermediates。